U.S. patent application number 12/718208 was filed with the patent office on 2011-02-03 for novel crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid 471.
This patent application is currently assigned to AstraZeneca AB. Invention is credited to Gary Peter TOMKINSON.
Application Number | 20110028529 12/718208 |
Document ID | / |
Family ID | 42782026 |
Filed Date | 2011-02-03 |
United States Patent
Application |
20110028529 |
Kind Code |
A1 |
TOMKINSON; Gary Peter |
February 3, 2011 |
NOVEL CRYSTALLINE FORMS OF
4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID
471
Abstract
New crystalline forms of
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid;
their use in the inhibition of 11.beta.HSD1, processes for making
them and pharmaceutical compositions comprising them are also
described.
Inventors: |
TOMKINSON; Gary Peter;
(Macclesfield, GB) |
Correspondence
Address: |
MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON
DC
20004
US
|
Assignee: |
AstraZeneca AB
Sodertalje
SE
|
Family ID: |
42782026 |
Appl. No.: |
12/718208 |
Filed: |
March 5, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12364949 |
Feb 3, 2009 |
|
|
|
12718208 |
|
|
|
|
61082293 |
Jul 21, 2008 |
|
|
|
Current U.S.
Class: |
514/406 ;
548/374.1 |
Current CPC
Class: |
A61P 43/00 20180101;
A61P 31/10 20180101; C07D 231/14 20130101; A61P 3/00 20180101; A61P
3/10 20180101 |
Class at
Publication: |
514/406 ;
548/374.1 |
International
Class: |
A61K 31/415 20060101
A61K031/415; C07D 231/14 20060101 C07D231/14; A61P 3/10 20060101
A61P003/10 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 4, 2008 |
PK |
108/2008 |
Feb 11, 2008 |
GB |
PCT/GB2008/000454 |
Claims
1-38. (canceled)
39. A crystalline form of
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
having an X-ray diffraction pattern with peaks at the following
2-theta values measured using CuKa radiation: 18.7 and
11.7.degree..
40. A crystalline compound as claimed in claim 39 having an X-ray
powder diffraction pattern with peaks at the following 2-theta
values measured using CuKa radiation: 18.7, 11.7 and
19.2.degree..
41. A crystalline form of a compound as claimed in claim 39 having
an X-ray powder diffraction pattern with peaks at the following
2-theta values measured using CuKa radiation: 18.7, 11.7, 19.2,
7.8, 14.1, 14.9 and 9.4.degree..
42. A crystalline form of a compound as claimed in claim 39 having
an X-ray powder diffraction pattern with peaks at the following
2-theta values measured using CuKa radiation: 18.7, 11.7, 19.2,
7.8, 14.1, 14.9, 9.4, 15.6, 16.1 and 9.6.degree..
43. A crystalline compound as claimed in claim 39 having an X-ray
diffraction pattern, using CuKa radiation, substantially the same
as shown in FIG. 3.
44. A pharmaceutical composition, which comprises a compound
according to claim 39 in association with a
pharmaceutically-acceptable diluent or carrier.
45. A method of producing a 11.beta.HSD1 inhibitory effect by
administering an effective amount of a compound according to claim
39 to a mammal in need of such treatment.
46. A method according to claim 45 wherein the 11.beta.HSD1
inhibitory effect is to treat type 2 diabetes.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Divisional Application of copending
U.S. patent application Ser. No. 12/364,949, filed Feb. 3, 2009,
which claims the benefit of U.S. Provisional Application No.
61/082,293, filed Jul. 21, 2008, Pakistan Application No. 108/2008,
filed Feb. 4, 2008 and International Application No.
PCT/GB2008/000454, filed Feb. 11, 2008, all of which are herein
incorporated by reference in their entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] Not Applicable.
NAMES OF PARTIES TO A JOINT RESEARCH AGREEMENT
[0003] Not Applicable.
INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT
DISC
[0004] Not Applicable.
BACKGROUND OF THE INVENTION
[0005] 1. Field of the Invention
[0006] This invention relates to novel crystalline forms of
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
(the Agent). The Agent possesses human 11-.beta.-hydroxysteroid
dehydrogenase type 1 enzyme (11.beta.HSD1) inhibitory activity and
accordingly has value in the treatment of disease states including
metabolic syndrome and are useful in methods of treatment of a
warm-blooded animal, such as man. The invention also relates to
processes for the manufacture of the crystalline forms of the
Agent, to pharmaceutical compositions containing them and to their
use in the manufacture of medicaments to inhibit 11.beta.HSD1 in a
warm-blooded animal, such as man.
[0007] The Agent is illustrated in Formula (I) hereinafter:
##STR00001##
[0008] 2. Description of Related Art
[0009] Glucocorticoids (cortisol in man, corticosterone in rodents)
are counter regulatory hormones i.e. they oppose the actions of
insulin (Dallman M F, Strack A M, Akana S F et al. 1993; Front
Neuroendocrinol 14, 303-347). They regulate the expression of
hepatic enzymes involved in gluconeogenesis and increase substrate
supply by releasing glycerol from adipose tissue (increased
lipolysis) and amino acids from muscle (decreased protein synthesis
and increased protein degradation). Glucocorticoids are also
important in the differentiation of pre-adipocytes into mature
adipocytes which are able to store triglycerides (Bujalska I J et
al. 1999; Endocrinology 140, 3188-3196). This may be critical in
disease states where glucocorticoids induced by "stress" are
associated with central obesity which itself is a strong risk
factor for type 2 diabetes, hypertension and cardiovascular disease
(Bjorntorp P & Rosmond R 2000; Int. J. Obesity 24,
S80-S85).
[0010] It is now well established that glucocorticoid activity is
controlled not simply by secretion of cortisol but also at the
tissue level by intracellular interconversion of active cortisol
and inactive cortisone by the 11-beta hydroxysteroid
dehydrogenases, 11.beta.HSD1 (which activates cortisone) and
11.beta.HSD2 (which inactivates cortisol) (Sandeep T C & Walker
B R 2001 Trends in Endocrinol & Metab. 12, 446-453). That this
mechanism may be important in man was initially shown using
carbenoxolone (an anti-ulcer drug which inhibits both 11.beta.HSD1
and 2) treatment which (Walker B R et al. 1995; J. Clin.
Endocrinol. Metab. 80, 3155-3159) leads to increased insulin
sensitivity indicating that 11.beta.HSD1 may well be regulating the
effects of insulin by decreasing tissue levels of active
glucocorticoids (Walker B R et al. 1995; J. Clin. Endocrinol.
Metab. 80, 3155-3159).
[0011] Clinically, Cushing's syndrome is associated with cortisol
excess which in turn is associated with glucose intolerance,
central obesity (caused by stimulation of pre-adipocyte
differentiation in this depot), dyslipidaemia and hypertension.
Cushing's syndrome shows a number of clear parallels with metabolic
syndrome. Even though the metabolic syndrome is not generally
associated with excess circulating cortisol levels (Jessop D S et
al. 2001; J. Clin. Endocrinol. Metab. 86, 4109-4114) abnormally
high 11.beta.HSD1 activity within tissues would be expected to have
the same effect. In obese men it was shown that despite having
similar or lower plasma cortisol levels than lean controls,
11.beta.HSD1 activity in subcutaneous fat was greatly enhanced
(Rask E et al. 2001; J. Clin. Endocrinol. Metab. 1418-1421).
Furthermore, the central fat, associated with the metabolic
syndrome expresses much higher levels of 11.beta.HSD1 activity than
subcutaneous fat (Bujalska I J et al. 1997; Lancet 349, 1210-1213).
Thus there appears to be a link between glucocorticoids,
11.beta.HSD1 and the metabolic syndrome.
[0012] 11.beta.HSD1 knock-out mice show attenuated
glucocorticoid-induced activation of gluconeogenic enzymes in
response to fasting and lower plasma glucose levels in response to
stress or obesity (Kotelevtsev Y et al. 1997; Proc. Natl. Acad.
Sci. USA 94, 14924-14929) indicating the utility of inhibition of
11.beta.HSD1 in lowering of plasma glucose and hepatic glucose
output in type 2 diabetes. Furthermore, these mice express an
anti-atherogenic lipoprotein profile, having low triglycerides,
increased HDL cholesterol and increased apo-lipoprotein AI levels.
(Morton N M et al. 2001; J. Biol. Chem. 276, 41293-41300). This
phenotype is due to an increased hepatic expression of enzymes of
fat catabolism and PPAR.alpha.. Again this indicates the utility of
11.beta.HSD1 inhibition in treatment of the dyslipidaemia of the
metabolic syndrome.
[0013] The most convincing demonstration of a link between the
metabolic syndrome and 11.beta.HSD1 comes from recent studies of
transgenic mice over-expressing 11.beta.HSD1 (Masuzaki H et al.
2001; Science 294, 2166-2170). When expressed under the control of
an adipose specific promoter, 11.beta.HSD1 transgenic mice have
high adipose levels of corticosterone, central obesity, insulin
resistant diabetes, hyperlipidaemia and hyperphagia. Most
importantly, the increased levels of 11.beta.HSD1 activity in the
fat of these mice are similar to those seen in obese subjects.
Hepatic 11.beta.HSD1 activity and plasma corticosterone levels were
normal, however, hepatic portal vein levels of corticosterone were
increased 3 fold and it is thought that this is the cause of the
metabolic effects in liver.
[0014] Overall it is now clear that the complete metabolic syndrome
can be mimicked in mice simply by overexpressing 11.beta.HSD1 in
fat alone at levels similar to those in obese man.
[0015] 11.beta.HSD1 tissue distribution is widespread and
overlapping with that of the glucocorticoid receptor. Thus,
11.beta.HSD1 inhibition could potentially oppose the effects of
glucocorticoids in a number of physiological/pathological roles.
11.beta.HSD1 is present in human skeletal muscle and glucocorticoid
opposition to the anabolic effects of insulin on protein turnover
and glucose metabolism are well documented (Whorwood C B et al.
2001; J. Clin. Endocrinol. Metab. 86, 2296-2308). Skeletal muscle
must therefore be an important target for 11.beta.HSD1 based
therapy.
[0016] Glucocorticoids also decrease insulin secretion and this
could exacerbate the effects of glucocorticoid induced insulin
resistance. Pancreatic islets express 11.beta.HSD1 and
carbenoxolone can inhibit the effects of 11-dehydrocorticosterone
on insulin release (Davani B et al. 2000; J. Biol. Chem. 275,
34841-34844). Thus in treatment of diabetes 11.beta.HSD1 inhibitors
may not only act at the tissue level on insulin resistance but also
increase insulin secretion itself.
[0017] Skeletal development and bone function is also regulated by
glucocorticoid action. 11.beta.HSD1 is present in human bone
osteoclasts and osteoblasts and treatment of healthy volunteers
with carbenoxolone showed a decrease in bone resorption markers
with no change in bone formation markers (Cooper M S et al 2000;
Bone 27, 375-381) Inhibition of 11.beta.HSD1 activity in bone could
be used as a protective mechanism in treatment of osteoporosis.
[0018] Glucocorticoids may also be involved in diseases of the eye
such as glaucoma. 11.beta.HSD1 has been shown to affect intraocular
pressure in man and inhibition of 11.beta.HSD1 may be expected to
alleviate the increased intraocular pressure associated with
glaucoma (Rauz S et al. 2001; Investigative Opthalmology &
Visual Science 42, 2037-2042).
[0019] There appears to be a convincing link between 11.beta.HSD1
and the metabolic syndrome both in rodents and in humans. Evidence
suggests that a drug which specifically inhibits 11.beta.HSD1 in
type 2 obese diabetic patients will lower blood glucose by reducing
hepatic gluconeogenesis, reduce central obesity, improve the
atherogenic lipoprotein phenotype, lower blood pressure and reduce
insulin resistance. Insulin effects in muscle will be enhanced and
insulin secretion from the beta cells of the islet may also be
increased.
[0020] Currently there are two main recognised definitions of
metabolic syndrome.
1) The Adult Treatment Panel (ATP III 2001 JMA) definition of
metabolic syndrome indicates that it is present if the patient has
three or more of the following symptoms: Waist measuring at least
40 inches (102 cm) for men, 35 inches (88 cm) for women; Serum
triglyceride levels of at least 150 mg/dl (1.69 mmol/l); HDL
cholesterol levels of less than 40 mg/dl (1.04 mmol/l) in men, less
than 50 mg/dl (1.29 mmol/l) in women; Blood pressure of at least
135/80 mm Hg; and/or Blood sugar (serum glucose) of at least 110
mg/dl (6.1 mmol/l). 2) The WHO consultation has recommended the
following definition which does not imply causal relationships and
is suggested as a working definition to be improved upon in due
course: The patient has at least one of the following conditions:
glucose intolerance, impaired glucose tolerance (IGT) or diabetes
mellitus and/or insulin resistance; together with two or more of
the following:
Raised Arterial Pressure;
[0021] Raised plasma triglycerides
Central Obesity
Microalbuminuria
BRIEF SUMMARY OF THE INVENTION
[0022] We have found that the Agent, or a
pharmaceutically-acceptable salt thereof, is an effective
11.beta.HSD1 inhibitor, and accordingly has value in the treatment
of disease states associated with metabolic syndrome. We have also
found that the compound of the invention has improved properties,
which would make it a better candidate for use as a
pharmaceutical.
[0023] We have now discovered further crystalline forms of the
Agent. These forms will be referred to as Form 2, Form 3 and Form
4.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIG. 1 shows an X-ray powder diffraction pattern of
crystalline Form 2 of the Agent.
[0025] FIG. 2 depicts a DSC thermogram of crystalline Form 2 of the
Agent.
[0026] FIG. 3 shows an X-ray powder diffraction pattern of
crystalline Form 3 of the Agent.
[0027] FIG. 4 depicts a DSC thermogram of crystalline Form 3 of the
Agent.
[0028] FIG. 5 shows an X-ray powder diffraction pattern of
crystalline Form 4 of the Agent.
[0029] FIG. 6 depicts a DSC thermogram of crystalline Form 4 of the
Agent.
[0030] FIG. 7 depicts a DSC thermogram of a more pure sample of
crystalline Form 4 of the Agent.
DETAILED DESCRIPTION OF THE INVENTION
[0031] Accordingly one aspect of the invention relates to a
crystalline form of
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
(Form 2), which has an X-ray diffraction pattern measured with at
least one specific peak at about 2-theta=18.0.
[0032] The 2-theta (.theta.) values were measured using CuKa
radiation.
[0033] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with at least two specific peaks at about
2-theta=18.0.degree. and 17.7.degree..
[0034] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=18.0, 17.7
and 18.4.degree..
[0035] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=18.0,
17.7, 18.4, 8.9 and 20.5.degree..
[0036] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=18.0,
17.7, 18.4, 8.9, 20.5, 10.4, 21.9, 13.4, 27.6 and 16.7.degree..
[0037] According to the present invention there is provided
crystalline form of the Agent, Form 2 which has an X-ray powder
diffraction pattern, using CuKa radiation, substantially the same
as the X-ray powder diffraction pattern shown in FIG. 1.
[0038] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with at least one specific peak at
2-theta=18.0.degree. plus or minus 0.5.degree. 2-theta.
[0039] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with at least two specific peaks at
2-theta=18.0.degree. and 17.7.degree. wherein said values may be
plus or minus 0.5.degree. 2-theta.
[0040] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.0, 17.7 and
18.4.degree. wherein said values may be plus or minus 0.5.degree.
2-theta.
[0041] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.0, 17.7,
18.4, 8.9 and 20.5.degree. wherein said values may be plus or minus
0.5.degree. 2-theta.
[0042] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.0, 17.7,
18.4, 8.9, 20.5, 10.4, 21.9, 13.4, 27.6 and 16.7.degree. wherein
said values may be plus or minus 0.5.degree. 2-theta.
[0043] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with at least one specific peak at
2-theta=18.0.degree..
[0044] According to the present invention there is provided a
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with at least two specific peaks at
2-theta=18.0 and 17.7.degree..
[0045] According to the present invention there is provided
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.0, 17.7 and
18.4.degree..
[0046] According to the present invention there is provided
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.0, 17.7,
18.4, 8.9 and 20.5.degree.
[0047] According to the present invention there is provided
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta==18.0, 17.7,
18.4, 8.9, 20.5, 10.4, 21.9, 13.4, 27.6 and 16.7.degree..
[0048] According to the present invention there is provided
crystalline form of the Agent, Form 2, which has an X-ray powder
diffraction pattern, using CuKa radiation, as shown in FIG. 1.
TABLE-US-00001 TABLE A Ten most Prominent X-Ray Powder Diffraction
peaks Form 2 of the Agent Angle 2- Relative Theta (2.theta.)
Intensity % Intensity 17.954 100 vs 17.656 77.4 vs 18.414 47.9 vs
8.869 30.5 vs 20.498 28.7 vs 10.415 21.3 s 21.880 15.1 s 13.391
11.4 s 27.576 11.4 s 16.729 10.8 s vs = very strong s = strong
[0049] DSC analysis shows Form 2 is a high melting solid with an
onset of melting at 309.9 C. The DSC thermogram is depicted in FIG.
2
[0050] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with at a peak at about
2-theta=18.7.degree..
[0051] The 2-theta (.theta.) values were measured using CuKa
radiation.
[0052] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with at least two specific peaks at about
2-theta=18.7.degree. and 11.7.degree..
[0053] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=18.7, 11.7
and 19.2.degree..
[0054] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=18.7,
11.7, 19.2, 7.8, 14.1, 14.9 and 9.4.degree..
[0055] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=18.7,
11.7, 19.2, 7.8, 14.1, 14.9, 9.4, 15.6, 16.1 and 9.6.degree..
[0056] According to the present invention there is provided
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern, using CuKa radiation, substantially the same
as the X-ray powder diffraction pattern shown in FIG. 3.
[0057] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with at least one specific peak at
2-theta=18.7.degree. plus or minus 0.5.degree. 2-theta.
[0058] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with at least two specific peaks at
2-theta=18.7.degree. and 11.7.degree. wherein said values may be
plus or minus 0.5.degree. 2-theta.
[0059] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.7, 11.7 and
19.2.degree. wherein said values may be plus or minus 0.5.degree.
2-theta.
[0060] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.7, 11.7,
19.2, 7.8, 14.1, 14.9 and 9.4.degree. wherein said values may be
plus or minus 0.5.degree. 2-theta.
[0061] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta==18.7, 11.7,
19.2, 7.8, 14.1, 14.9, 9.4, 15.6, 16.1 and 9.6.degree. wherein said
values may be plus or minus 0.5.degree. 2-theta.
[0062] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with at least one specific peak at
2-theta=18.7.degree..
[0063] According to the present invention there is provided a
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with at least two specific peaks at
2-theta=18.7 and 11.7.degree..
[0064] According to the present invention there is provided
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.7, 11.7 and
19.2.degree..
[0065] According to the present invention there is provided
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.7, 11.7,
19.2, 7.8, 14.1, 14.9, 9.4.degree..
[0066] According to the present invention there is provided
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=18.7, 11.7,
19.2, 7.8, 14.1, 14.9, 9.4, 15.6, 16.1 and 9.6.degree..
[0067] According to the present invention there is provided
crystalline form of the Agent, Form 3, which has an X-ray powder
diffraction pattern, using CuKa radiation, as shown in FIG. 3.
TABLE-US-00002 TABLE B Ten most Prominent X-Ray Powder Diffraction
peaks Form 3 of the Agent Angle 2- Relative Theta (2.theta.)
Intensity % Intensity 18.694 100.0 vs 11.704 32.0 vs 19.209 29.9 vs
7.810 28.8 vs 14.084 26.8 vs 14.892 26.3 vs 9.351 25.1 vs 15.598
21.5 s 16.079 18.1 s 9.610 17.5 s vs = very strong s = strong
[0068] DSC analysis shows Form 3 has an onset of melting at
309.3.degree. C. The DSC thermogram is depicted in FIG. 4.
[0069] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with at a peak at about
2-theta=16.2.degree..
[0070] The 2-theta (A) values were measured using CuKa
radiation.
[0071] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with at least two specific peaks at about
2-theta=16.2.degree. and 20.6.degree..
[0072] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=16.2, 20.6
and 17.7.degree..
[0073] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=16.2,
20.6, 17.7, 10.8 and 15.5.degree..
[0074] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at about 2-theta=16.2,
20.6, 17.7, 10.8, 15.5, 20.9, 26.1, 11.6, 26.7 and
18.1.degree..
[0075] According to the present invention there is provided
crystalline form of the Agent, Form 4 which has an X-ray powder
diffraction pattern, using CuKa radiation, substantially the same
as the X-ray powder diffraction pattern shown in FIG. 5.
[0076] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with at least one specific peak at
2-theta=16.2.degree. plus or minus 0.5.degree. 2-theta.
[0077] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with at least two specific peaks at
2-theta=16.2.degree. and 20.6.degree. wherein said values may be
plus or minus 0.5.degree. 2-theta.
[0078] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.2, 20.6 and
17.7.degree. wherein said values may be plus or minus 0.5.degree.
2-theta.
[0079] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.2, 20.6,
17.7, 10.8 and 15.5.degree. wherein said values may be plus or
minus 0.5.degree. 2-theta.
[0080] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.2, 20.6,
17.7, 10.8, 15.5, 20.9, 26.1, 11.6, 26.7 and 18.1.degree. wherein
said values may be plus or minus 0.5.degree. 2-theta.
[0081] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with at least one specific peak at
2-theta=16.2.degree..
[0082] According to the present invention there is provided a
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with at least two specific peaks at
2-theta=16.2 and 20.6.degree..
[0083] According to the present invention there is provided
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.2, 20.6 and
17.7.degree..
[0084] According to the present invention there is provided
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.2, 20.6,
17.7, 10.8 and 15.5.degree..
[0085] According to the present invention there is provided
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.2, 20.6,
17.7, 10.8, 15.5, 20.9, 26.1, 11.6 and 26.7.degree..
[0086] According to the present invention there is provided
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern, using CuKa radiation, as shown in FIG. 5.
TABLE-US-00003 TABLE C Ten most Prominent X-Ray Powder Diffraction
peaks Form 4 of the Agent Angle 2- Relative Theta (2.theta.)
Intensity % Intensity 16.165 100.0 vs 20.567 45.2 vs 17.652 43.7 vs
10.826 42.8 vs 15.476 29.4 vs 20.944 24.6 s 26.131 22.3 s 11.588
17.9 s 26.709 13.5 s 18.138 13.4 s vs = very strong s = strong
[0087] DSC analysis of Form 4 shows an initial event with an onset
at 254.0.degree. C. and a peak at 262.0.degree. C. followed by a
subsequent melt with an onset of 312.0.degree. C. Thus onset of
melting of Form 4 is at about 312.0.degree. C. The DSC thermogram
is depicted in FIG. 6.
[0088] Another more pure sample of form 4 gave the XRD pattern and
d-spacing spectrum shown in FIG. 7. The position of the 2-theta
values and the d-spacing are shown in tables D and E
respectively.
TABLE-US-00004 TABLE D Diffraction Peaks for form 4 Pos.
[.degree.2Th.] 10.8 11.5 15.4 16.1 17.6 18.9 20.5 20.9 26.1
26.6
TABLE-US-00005 TABLE E d-Spacing for form 4 d-spacing [.ANG.] 8.2
7.7 5.8 5.5 5.0 4.7 4.3 4.3 3.4 3.3
[0089] The slight variation in 2-theta values in tables C and D may
be due to a measurement error of a diffraction angle in an X-ray
powder diffractogram as mentioned hereinbelow.
[0090] Thus in another aspect of the invention allowing for
measurement error, there is provided a crystalline form of the
Agent, Form 4, which has an X-ray powder diffraction pattern with
at least two specific peaks at 2-theta=16.1 and 20.5.degree..
[0091] According to the present invention there is provided
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.1, 20.5 and
17.6.degree..
[0092] According to the present invention there is provided
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.1, 20.5,
17.6, 10.8 and 15.4.degree..
[0093] According to the present invention there is provided
crystalline form of the Agent, Form 4, which has an X-ray powder
diffraction pattern with specific peaks at 2-theta=16.1, 20.5,
17.6, 10.8, 15.4, 20.9 and 26.1.degree..
[0094] When it is stated that the present invention relates to a
crystalline form of Forms 2, 3 and 4, the degree of crystallinity
is conveniently greater than about 60%, more conveniently greater
than about 80%, preferably greater than about 90% and more
preferably greater than about 95%. Most preferably the degree of
crystallinity is greater than about 98%.
[0095] In another aspect the invention relates to the Agent as a
crystalline form 2.
[0096] In another aspect the invention relates to the Agent as a
crystalline form 3.
[0097] In another aspect the invention relates to the Agent as a
crystalline form 4.
[0098] In another aspect the invention relates to a crystalline
form 2 of the Agent substantially free of crystalline form 1.
[0099] In another aspect the invention relates to a crystalline
form 3 of the Agent substantially free of crystalline form 1.
[0100] In another aspect the invention relates to a crystalline
form 4 of the Agent substantially free of crystalline form 1.
[0101] A crystalline form substantially free of form 1 means a
crystalline form having less than 30% form 1. In another aspect,
`substantially free`, means having less that 20% form 1. In another
aspect, `substantially free`, means having less that 10% form 1. In
yet another aspect, `substantially free`, means having less that 5%
form 1. In yet another aspect, `substantially free`, means having
less that 1% form 1.
[0102] The Forms 2, 3 and 4 provide X-ray powder diffraction
patterns substantially the same as the X-ray powder diffraction
patterns shown in FIGS. 1, 2 and 3 and has substantially the ten
most prominent peaks (angle 2-theta values) shown in Tables A, B
and C. It will be understood that the 2-theta values of the X-ray
powder diffraction pattern may vary slightly from one machine to
another or from one sample to another, and so the values quoted are
not to be construed as absolute.
[0103] It is known that an X-ray powder diffraction pattern may be
obtained which has one or more measurement errors depending on
measurement conditions (such as equipment or machine used). In
particular, it is generally known that intensities in an X-ray
powder diffraction pattern may fluctuate depending on measurement
conditions. Therefore it should be understood that the Forms 2, 3
and 4 of the present invention are not limited to the crystals that
provide X-ray powder diffraction patterns identical to the X-ray
powder diffraction pattern shown in FIGS. 1, 2 and 3, and any
crystals providing X-ray powder diffraction patterns substantially
the same as those shown in FIGS. 1, 2 and 3 fall within the scope
of the present invention. A person skilled in the art of X-ray
powder diffraction is able to judge the substantial identity of
X-ray powder diffraction patterns.
[0104] Persons skilled in the art of X-ray powder diffraction will
realise that the relative intensity of peaks can be affected by,
for example, grains above 30 microns in size and non-unitary aspect
ratios, which may affect analysis of samples. The skilled person
will also realise that the position of reflections can be affected
by the precise height at which the sample sits in the
diffractometer and the zero calibration of the diffractometer. The
surface planarity of the sample may also have a small effect. Hence
the diffraction pattern data presented are not to be taken as
absolute values. (Jenkins, R & Snyder, R. L. `Introduction to
X-Ray Powder Diffractometry` John Wiley & Sons 1996; Bunn, C.
W. (1948), Chemical Crystallography, Clarendon Press, London; Klug,
H. P. & Alexander, L. E. (1974), X-Ray Diffraction
Procedures).
[0105] Generally, a measurement error of a diffraction angle in an
X-ray powder diffractogram is about 5% or less, in particular plus
or minus 0.5.degree. 2-theta. Typically plus or minus 0.2.degree.
2-theta. Such degree of a measurement error should be taken into
account when considering the X-ray powder diffraction patterns in
FIGS. 1, 2, 3 and 4 and when reading Tables A, B, C and D.
Furthermore, it should be understood that intensities might
fluctuate depending on experimental conditions and sample
preparation (preferred orientation).
Details of Techniques Used
X-Ray Powder Diffraction
TABLE-US-00006 [0106] TABLE B % Relative Intensity* Definition
25-100 vs (very strong) 10-25 s (strong) 3-10 m (medium) 1-3 w
(weak) *The relative intensities are derived from diffractograms
measured with fixed slits
Analytical Instrument: Siemens D5000.
[0107] The X-ray powder diffraction spectra were determined by
mounting a sample of the crystalline material on a Siemens single
silicon crystal (SSC) wafer mount and spreading out the sample into
a thin layer with the aid of a microscope slide. The sample was
spun at 30 revolutions per minute (to improve counting statistics)
and irradiated with X-rays generated by a copper long-fine focus
tube operated at 40 kV and 40 mA with a wavelength of 1.5406
angstroms. The collimated X-ray source was passed through an
automatic variable divergence slit set at V20 and the reflected
radiation directed through a 2 mm antiscatter slit and a 0.2 mm
detector slit. The sample was exposed for 1 second per 0.02 degree
2-theta increment (continuous scan mode) over the range 2 degrees
to 40 degrees 2-theta in theta-theta mode. The running time was 31
minutes and 41 seconds. The instrument was equipped with a
scintillation counter as detector. Control and data capture was by
means of a Dell Optiplex 686 NT 4.0 Workstation operating with
Diffract+ software. Persons skilled in the art of X-ray powder
diffraction will realise that the relative intensity of peaks can
be affected by, for example, grains above 30 microns in size and
non-unitary aspect ratios that may affect analysis of samples. The
skilled person will also realise that the position of reflections
can be affected by the precise height at which the sample sits in
the diffractometer and the zero calibration of the diffractometer.
The surface planarity of the sample may also have a small effect.
Hence the diffraction pattern data presented are not to be taken as
absolute values.
Differential Scanning Calorimetry
Analytical Instrument: TA Instruments Q1000 DSC.
[0108] Typically less than 5 mg of material contained in a 40 .mu.l
aluminium pan fitted with a lid was heated over the temperature
range 25.degree. C. to 325.degree. C. at a constant heating rate of
10.degree. C. per minute. A purge gas using nitrogen was used--flow
rate 100 ml per minute.
[0109] Forms 2, 3 and 4 may be prepared by competitive slurring
from form 1 or seeding. Conveniently form 2 may be prepared by
competitive slurrying in acetonitrile. In particular, this is
carried out in a temperature range of 45-55.degree. C., for example
about 50.degree. C. Conveniently form 3 may be prepared by
competitive slurrying in methanol. In particular, this is carried
out in a temperature range of 15-30.degree. C., for example about
ambient. Conveniently form 4 may be prepared by competitive
slurrying in ethyl acetate. In particular, this is carried out in a
temperature range of 15-30.degree. C., for example about ambient.
In addition, form 4 may be prepared by competitive slurrying in
acetone or acetonitrile at elevated temperatures.
[0110] As stated hereinbefore the Agent possesses 11.beta.HSD1
inhibitory activity. These properties may be assessed using the
following assay.
Assays
[0111] The conversion of cortisone to the active steroid cortisol
by 11.beta.HSD1 oxo-reductase activity, can be measured using a
competitive homogeneous time resolved fluorescence assay (HTRF)
(CisBio International, R&D, Administration and Europe Office,
In Vitro Technologies-HTRF.RTM./Bioassays BP 84175, 30204
Bagnols/Ceze Cedex, France. Cortisol bulk HTRF kit: Cat No.
62CORPEC).
[0112] The evaluation of the compound described herein was carried
out using a baculovirus expressed N terminal 6-His tagged full
length human 11.beta.HSD1 enzyme (*1). The enzyme was purified from
a detergent solublised cell lysate, using a copper chelate column.
Inhibitors of 11.beta.HSD1 reduce the conversion of cortisone to
cortisol, which is identified by an increase in signal, in the
above assay.
[0113] The compound to be tested was dissolved in dimethyl
sulphoxide (DMSO) to 10 mM and diluted further in assay buffer
containing 1% DMSO to 10 fold the final assay concentration.
Diluted compound was then plated into black 384 well plates
(Matrix, Hudson N.H., USA).
[0114] The assay was carried out in a total volume of 20 .mu.l
consisting of cortisone (Sigma, Poole, Dorset, UK, 160 nM),
glucose-6-phosphate (Roche Diagnostics, 1 mM), NADPH (Sigma, Poole,
Dorset, 100 .mu.M), glucose-6-phosphate dehydrogenase (Roche
Diagnostics, 12.5 .mu.g/ml), EDTA (Sigma, Poole, Dorset, UK, 1 mM),
assay buffer (K.sub.2HPO.sub.4/KH.sub.2PO.sub.4, 100 mM) pH 7.5,
recombinant 11.beta.HSD1 [using an appropriate dilution to give a
viable assay window--an example of a suitable dilution may be 1 in
1000 dilution of stock enzyme] plus test compound. The assay plates
were incubated for 25 minutes at 37.degree. C. after which time the
reaction was stopped by the addition of 10 .mu.l of 0.5 mM
glycerrhetinic acid plus conjugated cortisol (XL665 or D2). 10
.mu.l of anti-cortisol Cryptate was then added and the plates
sealed and incubated for 6 hours at room temperature. Fluorescence
at 665 nm and 620 nm was measured and the 665 nm:620 nm ratio
calculated using an Envision plate reader.
[0115] These data were then used to calculate IC.sub.50 values for
each compound (Origin 7.5, Microcal software, Northampton Mass.,
USA) and/or the % inhibition at 30 .mu.M of compound. *1 The
Journal of Biological Chemistry, Vol. 26, No 25, pp 16653-16658
The following results were obtained: Reference Example 1 IC50 0.008
.mu.M.
[0116] The oral bioavailability of the compound of the invention
may be tested as follows:
Determination of Bioavailability in PK Studies
[0117] Compounds are dosed intravenously at 2 mg/kg (2 ml/kg) and
orally at 5 mg/kg (5 ml/kg) in a 25% HPBCD in sorrensons buffer pH
5.5 formulation. Blood samples (200 ul) are taken Predose, 0.25,
0.5, 1, 2, 3, 4, 5, 6, 8 and 24 h post dose for both routes and
plasma prepared by centrifugation. Plasma samples are analysed as
below. PK parameters (clearance, volume of distribution,
bioavailability, fraction absorbed etc.) are calculated by standard
PK methods using suitable PK software (WinNon-Lin).
Bioanalysis of Plasma Samples
[0118] The guidelines described are for the manual preparation of
plasma samples following single compound or cassette dosing of
project compounds to all PK species used within discovery DMPK.
Analysis by open access (LC-MS/MS) or manual approaches (LC-MS) is
described.
Contents
[0119] 1. Materials
[0120] 2. Generic Extraction Method
[0121] 3. Example Sample List Using Generic Plate Layout
[0122] 4. Open Access Batch Submission and System Checks
[0123] 5. Acceptance Criteria for Batch Pass
1. Materials
[0124] Solvents: Methanol, acetonitrile and DMSO Water: Purified or
HPLC grade 1 ml shallow 96-well plates OR eppendorf tubes 2 ml deep
well 96-well plates plus lids Blank (control) plasma
2. Generic Extraction Method
[0125] Solubilise compound(s) to 1 mg/ml using DMSO taking into
account salt factors if any. The DMSO stock(s) may be used to make
all calibration & quality control (QC) samples: 2.i Single
compound analysis 2.i.a Preparation of calibration and QC samples:
[0126] 1. Prepare standard solutions as follows:
TABLE-US-00007 [0126] Stock Volume Volume Standard Post plasma
diluted methanol stock conc. dilution conc. ng/ml ml ml ng/ml ng/ml
1 mg/ml 0.9 0.1 100,000 10,000 100,000 0.5 0.5 50,000 5,000 50,000
0.75 0.5 20,000 2,000 20,000 0.5 0.5 10,000 1,000 10,000 0.5 0.5
5,000 500 5,000 2 0.5 1,000 100 1,000 0.5 0.5 500 50 500 0.75 0.5
200 20 200 0.5 0.5 100 10 100 0.5 0.5 50 5 50 0.5 0.5 10 1
[0127] 2. Transfer 50 ul blank plasma to a well of a 1 ml 96-well
plate (shallow well) [0128] 3. Transfer 5 ul of each of the
standard solutions to further wells of the plate [0129] 4. Add 50
ul blank plasma to each of these wells. [0130] 5. To generate the
QC samples, add three aliquots of 5 ul of the 100 ng/ml, 1000 ng/ml
and 10,000 ng/ml standard solutions to the plate (3 QCs at each
concentration). [0131] 6. Add 50 ul blank plasma to each of these.
[0132] 7. Transfer 50 ul of each PK sample to the 1 ml 96-well
plate [0133] 8. Add 5 ul methanol (-compound) to each of the PK
samples [0134] 9. Ensure all dose formulations are well mixed by
vortex mixing. [0135] 10. Dilute intravenous (IV) and oral dose
(PO) formulations of expected concentration to 10 ug/ml in
methanol. (For example, a formulation made to an expected
concentration of 2 mg/ml would be diluted 1:200 to give 10 ug/ml
solution). [0136] 11. Add 6.times.50 ul aliquots of plasma to the
plate. Add 5 ul of diluted IV formulation to three of the wells,
repeat with PO formulation and remaining 3 wells. [0137] 12.
Precipitate proteins by adding 100 ul acetonitrile containing a
project related internal standard (at 1 ug/ml) to all calibration,
QC, PK and formulation samples. [0138] 13. Vortex mix the plate
before centrifugation at 4,000 g for 10 minutes. [0139] 14.
Transfer 100 ul of the supernatant to the wells of a 2 ml 96-well
plate (see following plate map). Care should be taken not to
disturb the pellet. [0140] 15. Add .about.1.5 ml of 50:50
Methanol:Water into the last well. [0141] 16. For analysis on
triple quad systems: add 400 ul water (HPLC grade) to each sample.
Gently mix. [0142] 17. Add 100 ul of the 100,000 ng/ml stock of
each of the standard solutions to the 2 ml plate and add 900 ul
water. Add a sample of internal standard to a further well (see
plate map). These are for compound tuning (denoted on the plate map
as tune solutions) [0143] 18. For analysis on platform systems: add
100 ul water (HPLC grade) to each sample. Gently mix. [0144] 19.
Manually tune all compounds using compound solutions prepared to
5,000 ng/ml (add 100 ul of the 50,000 ng/ml standard solutions to
900 ul water)
2.ii Cassette Dose Analysis
[0145] 2.iia Preparation of calibration and QC samples:
Note: For cassette dosing, the amount of methanol required to
dilute the 1 mg/ml stock will be adjusted according to the number
of compounds present.
[0146] 1. Add 100 ul of each 1 mg/ml stock required to a vial.
[0147] 2. Add the required volume of methanol to yield a total
volume of 1 ml.
[0148] 3. Perform all further steps as for single compound analysis
(steps 2-16 above).
2.iii In Cases where PK Samples Exceed the Upper Limit of
Quantification (ULOQ).
[0149] 1. Prepare a further calibration curve and QC samples as
above (steps 1-6).
[0150] 2. Transfer <50 ul (e.g. 25 ul) of the PK samples that
exceed the ULOQ.
[0151] 3. Add enough control plasma to these samples to yield a
final plasma volume of 50 ul. Make a note of the dilution made.
[0152] 4. Transfer 50 ul of all remaining PK samples.
[0153] 5. Prepare all formulation samples and extract all samples
as described above. (steps 8-16)
Note: Upper concentrations used to generate the calibration curve
may be reviewed, however, care must be taken to avoid saturation of
the HPLC column or MS equipment. It is for this reason that
dilution of PK samples is recommended.
2.iv In Cases of Poor Sensitivity (High Lower Limit of
Quantification).
[0154] Note: High LLOQ is taken as when most of the plasma
concentrations lie below the lower limit of quantification or where
the LLOQ is greater the 10 ng/ml. The following methods should be
applied when either of these scenarios is encountered.
[0155] According to a further aspect of the invention there is
provided a pharmaceutical composition, which comprises the Agent,
or a pharmaceutically-acceptable salt thereof, as defined
hereinbefore in association with a pharmaceutically-acceptable
diluent or carrier.
[0156] The compositions of the invention may be in a form suitable
for oral use (for example as tablets, lozenges, hard or soft
capsules, aqueous or oily suspensions, emulsions, dispersible
powders or granules, syrups or elixirs), for topical use (for
example as creams, ointments, gels, or aqueous or oily solutions or
suspensions), for administration by inhalation (for example as a
finely divided powder or a liquid aerosol), for administration by
insufflation (for example as a finely divided powder) or for
parenteral administration (for example as a sterile aqueous or oily
solution for intravenous, subcutaneous, intramuscular or
intramuscular dosing or as a suppository for rectal dosing). In
general, compositions in a form suitable for oral use are
preferred.
[0157] The compositions of the invention may be obtained by
conventional procedures using conventional pharmaceutical
excipients, well known in the art. Thus, compositions intended for
oral use may contain, for example, one or more colouring,
sweetening, flavouring and/or preservative agents.
[0158] Suitable pharmaceutically-acceptable excipients for a tablet
formulation include, for example, inert diluents such as lactose,
sodium carbonate, calcium phosphate or calcium carbonate,
granulating and disintegrating agents such as corn starch or
algenic acid; binding agents such as starch; lubricating agents
such as magnesium stearate, stearic acid or talc; preservative
agents such as ethyl or propyl p-hydroxybenzoate, and
anti-oxidants, such as ascorbic acid. Tablet formulations may be
uncoated or coated either to modify their disintegration and the
subsequent absorption of the active ingredient within the
gastrointestinal tract, or to improve their stability and/or
appearance, in either case, using conventional coating agents and
procedures well known in the art.
[0159] Compositions for oral use may be in the form of hard gelatin
capsules in which the active ingredient is mixed with an inert
solid diluent, for example, calcium carbonate, calcium phosphate or
kaolin, or as soft gelatin capsules in which the active ingredient
is mixed with water or an oil such as peanut oil, liquid paraffin,
or olive oil.
[0160] Aqueous suspensions generally contain the active ingredient
in finely powdered form together with one or more suspending
agents, such as sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose, sodium alginate,
polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or
wetting agents such as lecithin or condensation products of an
alkylene oxide with fatty acids (for example polyoxethylene
stearate), or condensation products of ethylene oxide with long
chain aliphatic alcohols, for example heptadecaethyleneoxycetanol,
or condensation products of ethylene oxide with partial esters
derived from fatty acids and a hexitol such as polyoxyethylene
sorbitol monooleate, or condensation products of ethylene oxide
with long chain aliphatic alcohols, for example
heptadecaethyleneoxycetanol, or condensation products of ethylene
oxide with partial esters derived from fatty acids and a hexitol
such as polyoxyethylene sorbitol monooleate, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and hexitol anhydrides, for example polyethylene sorbitan
monooleate. The aqueous suspensions may also contain one or more
preservatives (such as ethyl or propyl p-hydroxybenzoate,
anti-oxidants (such as ascorbic acid), colouring agents, flavouring
agents, and/or sweetening agents (such as sucrose, saccharine or
aspartame).
[0161] Oily suspensions may be formulated by suspending the active
ingredient in a vegetable oil (such as arachis oil, olive oil,
sesame oil or coconut oil) or in a mineral oil (such as liquid
paraffin). The oily suspensions may also contain a thickening agent
such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set out above, and flavouring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an anti-oxidant such as ascorbic
acid.
[0162] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water generally contain
the active ingredient together with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients such as sweetening,
flavouring and colouring agents, may also be present.
[0163] The pharmaceutical compositions of the invention may also be
in the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, such as olive oil or arachis oil, or a mineral oil,
such as for example liquid paraffin or a mixture of any of these.
Suitable emulsifying agents may be, for example,
naturally-occurring gums such as gum acacia or gum tragacanth,
naturally-occurring phosphatides such as soya bean, lecithin, an
esters or partial esters derived from fatty acids and hexitol
anhydrides (for example sorbitan monooleate) and condensation
products of the said partial esters with ethylene oxide such as
polyoxyethylene sorbitan monooleate. The emulsions may also contain
sweetening, flavouring and preservative agents.
[0164] Syrups and elixirs may be formulated with sweetening agents
such as glycerol, propylene glycol, sorbitol, aspartame or sucrose,
and may also contain a demulcent, preservative, flavouring and/or
colouring agent.
[0165] The pharmaceutical compositions may also be in the form of a
sterile injectable aqueous or oily suspension, which may be
formulated according to known procedures using one or more of the
appropriate dispersing or wetting agents and suspending agents,
which have been mentioned above. A sterile injectable preparation
may also be a sterile injectable solution or suspension in a
non-toxic parenterally-acceptable diluent or solvent, for example a
solution in 1,3-butanediol.
[0166] Compositions for administration by inhalation may be in the
form of a conventional pressurised aerosol arranged to dispense the
active ingredient either as an aerosol containing finely divided
solid or liquid droplets. Conventional aerosol propellants such as
volatile fluorinated hydrocarbons or hydrocarbons may be used and
the aerosol device is conveniently arranged to dispense a metered
quantity of active ingredient.
[0167] For further information on formulation the reader is
referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal
Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon
Press 1990.
[0168] The amount of active ingredient that is combined with one or
more excipients to produce a single dosage form will necessarily
vary depending upon the host treated and the particular route of
administration. For example, a formulation intended for oral
administration to humans will generally contain, for example, from
0.5 mg to 2 g of active agent compounded with an appropriate and
convenient amount of excipients which may vary from about 5 to
about 98 percent by weight of the total composition. Dosage unit
forms will generally contain about 1 mg to about 500 mg of an
active ingredient. For further information on Routes of
Administration and Dosage Regimes the reader is referred to Chapter
25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin
Hansch; Chairman of Editorial Board), Pergamon Press 1990.
[0169] We have found that the Agent, or a
pharmaceutically-acceptable salt thereof, is an effective
11.beta.HSD1 inhibitor, and accordingly has value in the treatment
of disease states associated with metabolic syndrome.
[0170] It is to be understood that where the term "metabolic
syndrome" is used herein, this relates to metabolic syndrome as
defined in 1) and/or 2) or any other recognised definition of this
syndrome. Synonyms for "metabolic syndrome" used in the art include
Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X. It
is to be understood that where the term "metabolic syndrome" is
used herein it also refers to Reaven's Syndrome, Insulin Resistance
Syndrome and Syndrome X.
[0171] According to a further aspect of the present invention there
is provided the Agent, or a pharmaceutically-acceptable salt
thereof, as defined hereinbefore for use in a method of
prophylactic or therapeutic treatment of a warm-blooded animal,
such as man.
[0172] Thus according to this aspect of the invention there is the
Agent, or a pharmaceutically-acceptable salt thereof, for use as a
medicament.
[0173] According to another feature of the invention there is
provided the use of the Agent, or a pharmaceutically-acceptable
salt thereof, in the manufacture of a medicament for use in the
production of an 11.beta.HSD1 inhibitory effect in a warm-blooded
animal, such as man.
[0174] Where production of or producing an 11.beta.HSD1 inhibitory
effect is referred to suitably this refers to the treatment of
metabolic syndrome. Alternatively, where production of an
11.beta.HSD1 inhibitory effect is referred to this refers to the
treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia,
hyperinsulinemia or hypertension, particularly type 2 diabetes and
obesity. Alternatively, where production of an 11.beta.HSD1
inhibitory effect is referred to this refers to the treatment of
glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders
or depression.
[0175] Alternatively, where production of an 11.beta.HSD1
inhibitory effect is referred to this refers to the treatment of
cognitive disorders, such as improving the cognitive ability of an
individual, for example by improvement of verbal fluency, verbal
memory or logical memory, or for treatment of mild cognitive
disorders. See for example WO03/086410 and references contained
therein, and Proceedings of National Academy of Sciences (PNAS),
2001, 98(8), 4717-4721.
[0176] Alternatively, where production of an 11.beta.HSD1
inhibitory effect is referred to this refers to the treatment of,
delaying the onset of and/or reducing the risk of
atherosclerosis--see for example J. Experimental Medicine, 2005,
202(4), 517-527.
[0177] Alternatively, where production of an 11.beta.HSD1
inhibitory effect is referred to this refers to the treatment of
Alzheimers and/or neurodegenerative disorders.
[0178] According to a further feature of this aspect of the
invention there is provided a method for producing an 11.beta.HSD1
inhibitory effect in a warm-blooded animal, such as man, in need of
such treatment which comprises administering to said animal an
effective amount of a compound of formula (1), or a
pharmaceutically-acceptable salt thereof.
[0179] In addition to their use in therapeutic medicine, the Agent,
or a pharmaceutically-salt thereof, are also useful as
pharmacological tools in the development and standardisation of in
vitro and in vivo test systems for the evaluation of the effects of
inhibitors of 11.beta.HSD1 in laboratory animals such as cats,
dogs, rabbits, monkeys, rats and mice, as part of the search for
new therapeutic agents.
[0180] The inhibition of 11.beta.HSD1 described herein may be
applied as a sole therapy or may involve, in addition to the
subject of the present invention, one or more other substances
and/or treatments. Such conjoint treatment may be achieved by way
of the simultaneous, sequential or separate administration of the
individual components of the treatment. Simultaneous treatment may
be in a single tablet or in separate tablets. For example agents
than might be co-administered with 11.beta.HSD1 inhibitors,
particularly those of the present invention, may include the
following main categories of treatment:
1) Insulin and insulin analogues; 2) Insulin secretagogues
including sulphonylureas (for example glibenclamide, glipizide),
prandial glucose regulators (for example repaglinide, nateglinide),
glucagon-like peptide 1 agonist (GLP1 agonist) (for example
exenatide, liraglutide) and dipeptidyl peptidase IV inhibitors
(DPP-IV inhibitors); 3) Insulin sensitising agents including
PPAR.gamma. agonists (for example pioglitazone and rosiglitazone);
4) Agents that suppress hepatic glucose output (for example
metformin); 5) Agents designed to reduce the absorption of glucose
from the intestine (for example acarbose); 6) Agents designed to
treat the complications of prolonged hyperglycaemia; e.g. aldose
reductase inhibitors 7) Other anti-diabetic agents including
phosotyrosine phosphatase inhibitors, glucose 6-phosphatase
inhibitors, glucagon receptor antagonists, glucokinase activators,
glycogen phosphorylase inhibitors, fructose 1,6 bisphosphastase
inhibitors, glutamine:fructose-6-phosphate amidotransferase
inhibitors 8) Anti-obesity agents (for example sibutramine and
orlistat); 9) Anti-dyslipidaemia agents such as, HMG-CoA reductase
inhibitors (statins, eg pravastatin); PPAR.alpha. agonists
(fibrates, eg gemfibrozil); bile acid sequestrants
(cholestyramine); cholesterol absorption inhibitors (plant stanols,
synthetic inhibitors); ileal bile acid absorption inhibitors
(IBATi), cholesterol ester transfer protein inhibitors and
nicotinic acid and analogues (niacin and slow release
formulations); 10) Antihypertensive agents such as, .beta. blockers
(eg atenolol, inderal); ACE inhibitors (eg lisinopril); calcium
antagonists (eg. nifedipine); angiotensin receptor antagonists (eg
candesartan), .alpha. antagonists and diuretic agents (eg.
furosemide, benzthiazide); 11) Haemostasis modulators such as,
antithrombotics, activators of fibrinolysis and antiplatelet
agents; thrombin antagonists; factor Xa inhibitors; factor VIIa
inhibitors; antiplatelet agents (eg. aspirin, clopidogrel);
anticoagulants (heparin and Low molecular weight analogues,
hirudin) and warfarin; 12) Anti-inflammatory agents, such as
non-steroidal anti-inflammatory drugs (eg. aspirin) and steroidal
anti-inflammatory agents (eg. cortisone); and 13) Agents that
prevent the reabsorption of glucose by the kidney (SGLT
inhibitors).
EXAMPLES
[0181] The invention will now be illustrated by the following
Examples in which, unless stated otherwise:
(i) temperatures are given in degrees Celsius (.degree. C.);
operations were carried out at room or ambient temperature, that
is, at a temperature in the range of 18-25.degree. C. and under an
atmosphere of an inert gas such as argon; (ii) evaporation of
solvent was carried out using a rotary evaporator under reduced
pressure (600-4000 Pa; 4.5-30 mmHg) with a bath temperature of up
to 60.degree. C.; (iii) chromatography means flash chromatography
on silica gel; (iv) in general, the course of reactions was
followed by TLC and reaction times are given for illustration only;
(v) yields are given for illustration only and are not necessarily
those which can be obtained by diligent process development;
preparations were repeated if more material was required; (vi)
where given, NMR data (.sup.1H) is in the form of delta values for
major diagnostic protons, given in parts per million (ppm) relative
to tetramethylsilane (TMS), determined at 300 or 400 MHz (unless
otherwise stated) using perdeuterio dimethyl sulfoxide
(DMSO-d.sub.6) as solvent, unless otherwise stated; peak
multiplicities are shown thus: s, singlet; d, doublet; dd, doublet
of doublets; dt, doublet of triplets; dm, doublet of multiplets; t,
triplet, m, multiplet; br, broad; (vii) chemical symbols have their
usual meanings; SI units and symbols are used; (viii) solvent
ratios are given in volume: volume (v/v) terms; (ix) mass spectra
(MS) were run with an electron energy of 70 electron volts in the
chemical ionisation (CI) mode using a direct exposure probe; where
indicated ionisation was effected by electron impact (EI), fast
atom bombardment (FAB) or electrospray (ESP); values for m/z are
given; generally, only ions which indicate the parent mass are
reported; (x) relative volume (rel vol) is the relative volume
compared to the amount of the key intermediate. Relative volume is
usually used to refer to the amount of solvent. For example if the
key intermediate is 100 g and 1000 ml of solvent is used, then this
is referred to as 10 rel vol of solvent; (xi) The following
abbreviations may be used below or in the process section
hereinbefore: [0182] Et.sub.2O diethyl ether [0183] DMF
dimethylformamide [0184] DCM dichloromethane [0185] THF
tetrahydrofuran [0186] DMSO dimethylsulfoxide [0187] EtOAc ethyl
acetate [0188] MTBE methyl tert-butyl ether [0189] DSC differential
scanning calorimetry
Reference Example 1
4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic
acid
##STR00002##
[0191] 2M aqueous sodium hydroxide solution (51.7 mL, 103.32 mmol)
was added to methyl
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoate
(Intermediate#1) (4.5 g, 10.33 mmol) in methanol (100 mL). The
mixture was stirred at 70.degree. C. for 1 hour and then cooled to
ambient temperature, concentrated under reduced pressure and
diluted with water (100 mL). The reaction mixture was adjusted to
pH 3 with 2M HCl. The reaction mixture was extracted with EtOAc
(500 mL) and washed sequentially with water (2.times.100 mL), and
saturated brine (50 mL). The organic layer was dried over MgSO4,
filtered and evaporated to give a pale yellow solid. The solid was
washed with EtOAc (20 mL), collected by filtration and dried under
vacuum to give
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
(3.89 g, 89%) as a cream crystalline solid.
[0192] .sup.1H NMR (400.13 MHz, DMSO-d.sub.6) .delta. 1.19 (9H, s),
1.49 (2H, d), 1.70-1.96 (10H, m), 2.09 (2H, d), 3.98-4.01 (1H, m),
7.49-7.53 (2H, m), 7.61 (1H, s), 8.06-8.09 (2H, m), 8.20 (1H, d),
13.30 (1H, s)
[0193] m/z (ESI+)(M+H)+=422
[0194] m.p. 308.8.degree. C. (onset)
[0195] Reference Example 1 may also be prepared as follows:
Aqueous sodium hydroxide (2M) (2.5 eq) was added portionwise over 5
minutes to a stirred suspension of methyl
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoate
(Intermediate#1) (1.0 eq) in methanol (10 vol) at 20.degree. C.
(exotherm 20-27.degree. C.). The resulting suspension was heated to
70.degree. C. (jacket temperature), (batch refluxes approx
60-65.degree. C.) for 1 hour (complete by LCMS). The orange
reaction mixture was cooled to 20.degree. C. (solution remained
slightly cloudy) and filtered through celite to remove a small
amount of solids. The filtrate was then poured into a flange flask
and water (25 vol) was added. The mixture was then adjusted to pH 3
with 2M HCl (approx 800-850 ml) (turns very thick). The aqueous was
then filtered and the pale yellow solid washed with water, sucked
dry overnight, and washed with acetonitrile and finally 1:1
acetonotrile/diethyl ether and dried under vacuum at 50.degree. C.
for 72 hours (weekend) to give
4-[4-(2-adamantylcarbamoyl)-5-tertbutyl-pyrazol-1-yl]benzoic acid
(80%) as a solid. Intermediate# 2: methyl 4-hydrazinylbenzoate
hydrochloride
##STR00003##
[0196] Hydrogen chloride 4M in Dioxan (100 mL, 399.60 mmol) was
added to 4-Hydrazinobenzoic acid (15.2 g, 99.90 mmol) in MeOH (200
mL). The resulting suspension was stirred at 90.degree. C. for 5
hours. After cooling to 20.degree. C. the precipitate was collected
by filtration, washed with Et2O (100 mL) and dried under vacuum to
afford 2-(4-(methoxycarbonyl)phenyl)hydrazinium chloride (16.50 g,
82%) as a cream crystalline solid.
[0197] m/z (ESI-)(M-H)-=165; HPLC t.sub.R=1.12 min.
[0198] 1H NMR (400.13 MHz, DMSO-d6) .delta. 3.81 (3H, s), 6.99-7.02
(2H, m), 7.86-7.90 (2H, m), 8.98 (1H, s), 10.47 (3H, s)
[0199] Intermediate# 2 may also be prepared as follows:
Methanolic hydrochloric acid solution (4M) (4 equiv., freshly
prepared) was added to a suspension of 4-hydrazinobenzoic acid (1
equiv.) in methanol (12.6 vols.), under nitrogen.
[0200] The mixture was stirred under reflux for three hours and
then cooled to below 15.degree. C. The solid was collected by
filtration, washed with MTBE (6.5 vols.) and dried in air to give
the product as a solid.
[0201] TLC DCM:MeOH, 9:1, Product R.sub.f 0.87
[0202] mp 233.8-234.6.degree. C.
Intermediate# 3: N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide
##STR00004##
[0203] A 1M solution of solution of lithium
bis(trimethylsilyl)amide in THF (22.84 ml, 22.84 mmol) was added to
THF (25 mL) and cooled under nitrogen to -78.degree. C. A solution
of 3,3-dimethyl-2-butanone (2.287 g, 22.84 mmol) in THF (25 mL) was
added drop wise over a period of 5 minutes. The resulting solution
was stirred at -78.degree. C. under nitrogen for 15 minutes. A
solution of 2-isocyanatoadamantane (prepared from 2-adamantylamine
hydrochloride by the method of R. Reck & C. Jochims Chem. Ber.
115 (1982) p 864) (3.68 g, 20.76 mmol) in THF (20 mL) was added
over a period of 5 minutes. The resulting solution was stirred at
-78.degree. C. for 1 hour and then allowed to warm to 20.degree. C.
over 1 h. The reaction mixture was poured into saturated NH.sub.4Cl
(150 mL) and extracted with EtOAc (2.times.100 mL), the organic
layer was washed with water (50 mL) and brine (50 mL) dried over
MgSO4, filtered and evaporated to afford a yellow oil. The crude
product was purified by flash silica chromatography, elution
gradient 0 to 50% EtOAc in isohexane. Pure fractions were
evaporated to dryness to afford
N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide (4.64 g, 81%) as a
white solid.
[0204] 1H NMR (400.13 MHz, DMSO-d.sub.6) .delta. 1.08-1.09 (9H, m),
1.50 (2H, d), 1.66-1.89 (10H, m), 1.95-2.00 (2H, m), 3.53 (1.4H,
s), 3.80-3.94 (1H, m), 5.30 (0.3H, s), 7.77-7.87 (1H, m), 14.43
(0.3H, s) (2:1 mixture of keto and enol forms)
[0205] m/z (ESI+)(M+H)+=278
[0206] Intermediate # 3 may also be prepared as follows:
Aqueous sodium hydroxide solution (3M) (5 vols.) was added to a
stirred suspension of 2-adamantylamine hydrochloride (1 equiv.) in
water (5 vols.). DCM (5 vols.) was added to the resulting thick
suspension and the phases separated. The aqueous was extracted with
DCM (4.times.5 vols.) and the combined organics concentrated to
give the free amine as a white solid.
[0207] Ethyl pivaloylacetate (1 equiv.) was added to a suspension
of the free amine in xylenes (6.5 vols.), under nitrogen, and the
mixture stirred under reflux for 6.5 hours. The batch was cooled to
room temperature and concentrated to dryness. The residue was
purged with toluene (3.times.1 vol.) followed by hexane (3.times.1
vol.). The resulting solid was digested in hexane at 50.degree. C.
for five minutes and then cooled to room temperature. The white
solid was filtered, washed with hexane (2 vols.) and dried in
air.
[0208] TLC Hexane:EtOAc, 1:1, Product R.sub.f 0.66
[0209] mp 124.5-125.1.degree. C.
Intermediate# 4:
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide
##STR00005##
[0210] N,N-Dimethylformamide dimethyl acetal (3.02 mL, 22.71 mmol)
was added to a stirred suspension of
N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide (Intermediate# 3)
(5.25 g, 18.93 mmol) in 1,4-dioxane (50 mL) under nitrogen. The
resulting mixture was stirred at 100.degree. C. for 2 hours. The
reaction mixture was evaporated to dryness and the resulting pale
cream solid was dried under vacuum to afford
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide (5.83 g, 93%).
[0211] 1H NMR (400.13 MHz, DMSO-d.sub.6) .delta. 1.13 (9H, s), 1.47
(2H, d), 1.69-1.83 (10H, m), 2.03 (2H, d), 2.92 (6H, s), 3.90 (1H,
d), 7.24 (1H, s), 7.94 (1H, d)
[0212] m/z (ESI+) (M+H)+=333
[0213] Intermediate#4 may also be prepared as follows:
N,N-Dimethylformamide dimethyl acetal (1.2 equivs.) was added to a
solution of N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide
(Intermediate# 3) (1 equiv.) in 1,4-dioxane (9.6 vols.) under
nitrogen. The mixture was heated under reflux for five hours and
then cooled to room temperature. The solvent was removed in vacuo
and the pale yellow solid used directly in the next stage.
[0214] TLC Hexane:EtOAc, 1:1, Product R.sub.f 0.94 (impurities:
R.sub.f 0.06+0.66)
[0215] mp 143.6-147.6.degree. C.
Intermediate#1: methyl
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoate
##STR00006##
[0216] Methyl 4-hydrazinylbenzoate hydrochloride (Intermediate# 2)
(3.04 g, 15.00 mmol) was added in one portion to
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide (Intermediate# 4) (4.99 g, 15 mmol) in ethanol (100 mL). 5
drops of acetic acid were added and the resulting solution was
stirred at 80.degree. C. for 2 hours. The reaction mixture was
concentrated and diluted with EtOAc (500 mL), and washed
sequentially with water (200 mL), and saturated brine (200 mL). The
organic layer was dried over MgSO4, filtered and evaporated to
afford crude product.
[0217] The crude product was purified by flash silica
chromatography, elution gradient 0 to 50% EtOAc in isohexane. Pure
fractions were evaporated to dryness to afford methyl
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoate
(4.66 g, 71.3%) as a yellow solid.
[0218] 1H NMR (400.13 MHz, DMSO-d.sub.6) .delta. 1.19 (9H, s), 1.50
(2H, d), 1.69-1.95 (10H, m), 2.09 (2H, d), 3.91 (3H, s), 3.99 (1H,
d), 7.53-7.56 (2H, m), 7.62 (1H, s), 8.09-8.12 (2H, m), 8.20 (1H,
d)
[0219] m/z (ESI+) (M+H)+=436
[0220] Intermediate# 1 may also be prepared as follows:
2-(4-(Methoxycarbonyl)phenyl)hydrazinium chloride (Intermediate# 2)
(1 equiv.) and then acetic acid (0.023 equivs.) were added to a
solution of
(2Z)--N-(2-adamantyl)-2-(dimethylamino-methylidene)-4,4-dimethyl-3-oxo-pe-
ntanamide (Intermediate# 4) (1 equiv.) in methanol (200 vols.),
under nitrogen. The mixture stirred under reflux for 1.5 hours,
cooled, concentrated to below 3.5 vols. and the resulting
suspension diluted with ethyl acetate (96 vols.). The suspension
was washed with water (34.4 vols.) giving a solution which was
washed with brine (34.4 vols.), dried (MgSO.sub.4) and concentrated
to dryness. The crude product was slurried in MTBE (9 vols.) and
stirred for 15 minutes. The pale yellow solid was filtered, washed
with MTBE (11.4 vols.) and dried under vacuum at 60.degree. C.
[0221] TLC DCM:MeOH, 9:1, Product R.sub.f 0.86 (trace impurity
R.sub.f 0.68)
[0222] mp 193.6-194.5.degree. C.
[0223] 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]
benzoic acid may also be prepared as follows:
Hydrochloric acid (34.5% w/w, 15.88 g, 5.48 g @100.0%, 0.1504 mole,
1.0 mol.eq) and water (70 ml, 1.4 rel.vol) were added to a
suspension of 4-hydrazinobenzoic acid (23.35 g, 22.88 g @100.0%,
0.1504 mole, 1.0 mol.eq) in methanol (1250 ml, 12.5 rel.vol). The
resulting suspension was stirred for 30 min at 20 to 25.degree. C.
and a solution of
N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-pentanami-
de (intermediate# 4) (53.47 g, 50.0 g @100.0%, 0.150 in 4 mole, 1.0
mol.eq) at 20-25.degree. C. in methanol (250 ml, 5.0 rel.vol)]
added over a period of 20 minutes followed by hydrochloric acid
(34.5% w/w, 2.38 g, 0.82 g @100.0%, 0.02264 mole, 0.15 mol.eq) and
water (70.0 ml, 1.4 rel.vol). The reaction mass temperature was
increased to 62-65.degree. C. and maintained for 90.0 min. For work
up methanol solution was concentrated atmospherically until the
residual volume 6.0 rel.vol (.about.300.0 ml) remained. The
resulting suspension was cooled to 20-25.degree. C. and stirred for
1.0 hr. The product was filtered and washed with ethyl acetate
(200.0 ml, 4.0 rel.vol) and sucked dry for 30 min. The product was
dried under vacuum (100 mbar) at 50.degree. C. for 8 hrs to give
crude 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]
benzoic acid (47.0 g, 73.0%).
[0224] 1H NMR (400.13 MHz, DMSO-d6) .delta. 1.19 (9H, s), 1.49 (2H,
d), 1.70-1.96 (10H, m), 2.09 (2H, d), 3.98-4.01 (1H, m), 7.49-7.53
(2H, m), 7.61 (1H, s), 8.06-8.09 (2H, m), 8.20 (1H, d), 13.30 (1H,
s)
[0225] m/z (ESI+)(M+H)+=422
[0226] m.p. 308.8.degree. C. (onset)
Chromatographic conditions: [HPLC]--
[0227] Zorbax SB-Aq, 150.times.4.6 mm, 5.mu. mobile phase used is
formic acid buffer using acetonitrile as organic solvent, 1.0
mL/min flow rate, injection volume is 20 .mu.L, run time is 18 mins
using UV detector wavelength 220,320 nm.
Retention Times[HPLC]
[0228] 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]
benzoic acid: (Relative retention time: 0.77 min) [0229]
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide (Retention time:14.2 min)
[0230] 10.0% w/w Aqueous sodium hydroxide solution (109.1 g, 10.91
g @100.0%, 0.2727 mole, 1.15 mol.eq) was added to a suspension of
crude 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]
benzoic acid (110.0 g, 100.0 g @100.0%, 0.2372 mole, 1.0 mol.eq) in
water (1000.0 ml, 10.0 rel.vol) and stirred for 15.0 min. The
un-dissolved product was filtered. To the resulting clear aqueous
solution (filtrate), was added toluene (600.0 ml, 6.0 rel.vol) and
stirred for 30.0 min. The reaction mass was settled for 1.0 hr for
phase separation. The aqueous layer was separated and filtered
through a Celite bed. To the aqueous layer was added methanol
(300.0 ml, 3.0 rel.vol). The pH of the aqueous layer was slowly
adjusted to 2.25 to 2.75 with dilute hydrochloric acid (3.8% w/w,
261.6 g, 9.94 @ 100.0%, 0.2727 mole, 1.15 mol.eq). The resulting
suspension was stirred for 1.5 to 2.0 hrs and the product filtered
and washed with 25.0% v/v methanol in water [500.0 ml, 5.0 rel.vol
(125 ml methanol and 475 ml water mixture). The product was dried
under vacuum (100 mbar) at 50 to 60.degree. C. for 16.0 hrs to
provide 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]
benzoic acid (85.0 g, 85.0%) (form 1).
Intermediate# 3
[0231] N-(2-Adamantyl)-4,4-dimethyl-3-oxo-pentanamide
##STR00007##
[0232] Intermediate# 3 may also be prepared as follows: Toluene
(400.0 ml, 4.0 rel.vol) was added to the solution of
2-adamantanamine hydrochloride (100.0 g, 98.0 g @ 100%, 0.5221
moles, 1.00 mol.eq) in water (500.0 ml, 5.0 rel.vol). 10.0% w/w
Aqueous sodium hydroxide solution (261.02 g, 26.1 g @ 100.0%,
0.6526 moles, 1.25 mol.eq) was added to the above solution and
stirred for 15 mins. The organic layer was separated from the
aqueous and washed with 5.0% w/w sodium chloride solution (300.0
ml, 3.0 rel.vol). Ethyl pivaloylacetate (115.9 g, 0.6526 moles,
1.25 mol.eq) was added in one portion to the organic layer. The
reaction mass was heated to reflux and toluene collected (550.0 ml,
5.5 rel.vol) azeotropically for 3 to 3.5 hrs, maintaining the
temperature at 110.degree. C. The reaction mass was cooled to
70-80.degree. C. and n-heptane (1000.0 ml, 10.0 rel.vol) added over
a period of 15 mins. It was further cooled to 25.degree. C. and the
resulting suspension was stirred for 1.0 hr. The suspended solid
was collected by filtration, washed with n-heptane (400.0 ml, 4.0
rel.vol) and the product dried under vacuum (100 mbar) at
50-55.degree. C. for 6.0 hrs to provide
N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide 113.0 g, 75.8% as a
white crystalline solid. 1H NMR (400.13 MHz, DMSO-d6) .delta.
1.08-1.09 (9H, m), 1.50 (2H, d), 1.66-1.89 (10H, m), 1.95-2.00 (2H,
m), 3.53 (1.4H, s), 3.80-3.94 (1H, m), 5.30 (0.3H, s), 7.77-7.87
(1H, m), 14.43 (0.3H, s) (2:1 mixture of keto and enol forms)
[0233] m/z (ESI+) (M+H)+=278
Chromatographic conditions:--(GC)
[0234] HP-5MS column, Helium as carrier gas, 1.0 mL/min flow rate,
solvent delay up to 1.5 min, oven temperature=initial 50.degree.
C., hold for 2 min, and then ramping @20.degree. C./min upto
280.degree. C. and injection volume is 1.0 .mu.L.
Retention Times(GC)
[0235] 2-Adamantanamine Hydrochloride (Retention time 8.1 min)
[0236] N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide (Relative
retention time: 1.617 min)
Intermediate# 4
[0237]
(2)-N-(2-Adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-
-pentanamide
##STR00008##
[0238] Intermediate# 4 may also be prepared as follows:
N,N-Dimethylformamide dimethyl acetal ((69.25 g, 63.02 g @100.0%,
0.5288 moles, 1.5 mol.eq) was added to a suspension of
N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide (intermediate 3)
(100 g, 97.8 g @ 100.0%, 0.3525 moles, 1.0 mol.eq) in n-heptane
(800.0 ml, 8.20 rel.vol) and toluene (350.0 ml, 3.58 rel.vol). The
reaction mass temperature was raised to 90-95.degree. C. and
maintained for 5.0 hrs then cooled to 80.degree. C. and n-heptane
(400.0 ml, 4.09 rel.vol) added. It was further cooled to 25.degree.
C. and the resulting suspension was collected by filtration, washed
with n-heptane (400.0 ml, 4.09 rel.vol) and the product sucked dry
for 30 min. The product was dried under vacuum (100 mbar) for 3.0
hrs at ambient temperature (20 to 25.degree. C.) to provide
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide (100 g, 79.7%)
[0239] 1H NMR (400.13 MHz, DMSO-d6) .delta. 1.13 (9H, s), 1.47 (2H,
d), 1.69-1.83 (10H, m), 2.03 (2H, d), 2.92 (6H, s), 3.90 (1H, d),
7.24 (1H, s), 7.94 (1H, d)
[0240] m/z (ESI+) (M+H)+=333
Chromatographic conditions:(HPLC)--
[0241] Sunfire C18, 150.times.4.6 mm, 5.mu., mobile phase used is
di-sodium hydrogen phosphate buffer using methanol as organic
solvent, 1.0 mL/min flow rate, injection volume is 20 .mu.L, run
time is 20 mins using refractive index detector.
Retention times(HPLC): [0242]
N-(2-Adamantyl)-4,4-dimethyl-3-oxo-pentanamide (Retention time:
11.0 min) [0243]
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-ox-
o-pentanamide (Relative retention time:1.18 min)
Reference Example 2
Synthesis of
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide
##STR00009##
[0245] To a suspension of 2-adamantanamine hydrochloride (25.0 g,
0.13 mol) in water (75.0 ml, 3.0 rel.vol) was added toluene (100.0
ml, 4.0 rel.vol). A 10.0% w/w aqueous sodium hydroxide solution
(1.25 mol.eq) was fed into the above solution and stirred for 10 to
15 minutes. The organic layer was separated and the aqueous layer
re-extracted with toluene (75.0 ml, 3.0 rel.vol) and combined with
the separated organic layer. The combined organic layer was washed
with 5.0% w/w sodium chloride solution (75 ml, 3.0 rel.vol.) and
separated. Ethyl pivaloylacetate (26.01 g, 0.15 mol) was added to
the organic layer was the reaction mass heated to reflux at 110 to
112.degree. C. The solvent (4 to 5 rel.vol.) was collected
azeotropically over 4 to 5 hours. The reaction mass was cooled to
40 to 45.degree. C. and n-heptane (200.0 ml, 8.0 rel.vol) added at
35 to 40.degree. C. followed by DMF-DMA (26.45 g, 0.20 mol) and
triethylamine (13.48 g, 0.13 mol) at 30 to 35.degree. C. The
reaction mass temperature was raised to 90 to 93.degree. C. and
maintained for 2 to 3 hours. The methanol generated as a by-product
was collected azeotropically during the reaction. The reaction was
cooled to 20 to 25.degree. C. and stirred for 1.0 hr at that
temperature. The precipitated product was filtered, bed washed with
n-heptane (100.0 ml, 4.0 rel.vol) and the product dried under
vacuum (50-100 mbar) at 35-40.degree. C. for 3 to 4 hours to give
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide (Yield, 86%). The product was packed under nitrogen
atmosphere and stored below 10.degree. C. as it was found to be
unstable at room temperature. Alternatively
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide may be prepared as follows:
To a suspension of 2-adamantanamine hydrochloride (25.0 g, 0.13
mol) in water (75.0 ml, 3.0 rel.vol) was added toluene (100.0 ml,
4.0 rel.vol). A 10.0% w/w aqueous sodium hydroxide solution (1.25
mol.eq) was fed into the above solution and stirred for 10 to 15
minutes. The organic layer was separated and the aqueous layer
re-extracted with toluene (75.0 ml, 3.0 rel.vol) and combined with
the separated organic layer. The combined organic layer was washed
with 5.0% w/w sodium chloride solution (75 ml, 3.0 rel.vol.) and
separated. Ethyl pivaloylacetate (26.01 g, 0.15 mol) was added to
the organic layer was the reaction mass heated to reflux at 110 to
112.degree. C. The solvent (4 to 5 rel.vol.) was collected
azeotropically over 4 to 5 hours. The reaction mass was cooled to
40 to 45.degree. C. and n-heptane (200.0 ml, 8.0 rel.vol) added at
35 to 40.degree. C. followed by DMF-DMA (26.45 g, 0.20 mol) at the
same temperature. The reaction mass temperature was raised to 85 to
90.degree. C. and maintained for 4 to 5 hours. The methanol
generated as a by-product was collected azeotropically during the
reaction. The reaction was cooled to 20 to 25.degree. C. and
stirred for 1.0 hr at that temperature. The precipitated product
was filtered, bed washed with n-heptane (100.0 ml, 4.0 rel.vol) and
the product dried under vacuum (50-100 mbar) at 35-40.degree. C.
for 3 to 4 hours to give
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide (Yield, 72%). The product was packed under nitrogen
atmosphere and stored below 10.degree. C. as it was found to be
unstable at room temperature.
Chromatographic Conditions:--
[0246] Sunfire C18, 150.times.4.6 mm, 5.mu., mobile phase used is
di-sodium hydrogen phosphate buffer using methanol as organic
solvent, 1.0 mL/min flow rate, injection volume is 20 .mu.L, run
time is 20 minutes using refractive index detector.
Retention Times:
[0247] N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide RT: 11.0 min
[0248]
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-ox-
o-pentanamide
[0249] RRT:1.18 min.
[0250] 1H NMR (400.13 MHz, DMSO-d6) .delta. 1.13 (9H, s), 1.47 (2H,
d), 1.69-1.83 (10H, m), 2.03 (2H, d), 2.92 (6H, s), 3.90 (1H, d),
7.24 (1H, s), 7.94 (1H, d)
[0251] m/z (ESI+) (M+H)+=333
[0252] If necessary the
N-(2-adamanytl)-4,4-dimethyl-3-oxopentanamide intermediate may be
isolated:
Chromatographic Conditions:--
[0253] HP-5MS column, Helium as carrier gas, 1.0 mL/min flow rate,
solvent delay up to 1.5 min, oven temperature=initial 50.degree.
C., hold for 2 min, and then ramping @20.degree. C./min up to
280.degree. C. and injection volume is 1.0 .mu.L.
Retention Times:
[0254] 2-Adamantanamine Hydrochloride RT 8.1 min
[0255] N-(2-adamantyl)-4,4-dimethyl-3-oxo-pentanamide RRT: 1.617
min.
[0256] 1H NMR (400.13 MHz, DMSO-d6) .delta. 1.08-1.09 (9H, m), 1.50
(2H, d), 1.66-1.89 (10H, m), 1.95-2.00 (2H, m), 3.53 (1.4H, s),
3.80-3.94 (1H, m), 5.30 (0.3H, s), 7.77-7.87 (1H, m), 14.43 (0.3H,
s) (2:1 mixture of keto and enol forms)
[0257] m/z (ESI+) (M+H)+=278
Synthesis of
4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
(Form-1)
##STR00010##
[0259] 4-Hydrazinobenzoic acid.HCl (14.11 g, 0.075 mol), and
(2)-N-(2-adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-oxo-penta-
namide (25.0 g, 0.075 mol) were put into a jacketed reactor
followed by isopropyl alcohol (315 ml, 12.6 rel. vol.) and water
(35 ml, 1.4 rel. vol.). The reaction mass was stirred at 20 to
25.degree. C. for about 45 to 60 minutes. The contents were heated
to reflux at 78 to 80.degree. C. and maintained at that temperature
for 90 minutes. The reaction mass was cooled to 50 to 55.degree. C.
and then water (150 ml, 6 rel. vol.) added at the same temperature.
The contents were further cooled to ambient temperature (20 to
25.degree. C.) and stirred for 1.0 hour at the same temperature.
The precipitated product was filtered and then washed with a
mixture of 1:1 ratio of isopropyl alcohol:water (250 ml, 10.0 rel.
vol.) to yield
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic
acid. The product was dried under vacuum at 50 to 55.degree. C. for
4 to 5 hours and used without further purification (Yield:
80%).
[0260] 1H NMR (400.13 MHz, DMSO-d6) .delta. 1.19 (9H, s), 1.49 (2H,
d), 1.70-1.96 (10H, m), 2.09 (2H, d), 3.98-4.01 (1H, m), 7.49-7.53
(2H, m), 7.61 (1H, s), 8.06-8.09 (2H, m), 8.20 (1H, d), 13.30 (1H,
s)
[0261] m/z (ESI+) (M+H)+=422
[0262] m.p. 308.8.degree. C. (onset)
Chromatographic Conditions:--
[0263] Zorbax SB-Aq, 150.times.4.6 mm, 5.mu. mobile phase used is
formic acid buffer using acetonitrile as organic solvent, 1.0
mL/min flow rate, injection volume is 20 .mu.L, run time is 18
minutes using UV detector wavelength 220,320 nm.
Retention Times:
[0264]
[((2)-N-(2-Adamantyl)-2-(dimethylaminomethylidene)-4,4-dimethyl-3-
-oxo-pentanamide RT 14.2 min [0265]
4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid
RRT 0.77 min (10.0 min) Intermediate RRT 0.79 (11.2 min)
Example 1
4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
(Form 2)
[0266] Approximately 50 mg of
4-[4-(2-adamantylcarbamoyl)-5-tertbutyl-pyrazol-1-yl]benzoic acid
as prepared above (Reference Example 1--Form 1) was placed in a
vial with a magnetic flea, and approximately 2 ml of acetonitrile
added. The vial was then sealed tightly with a cap. The slurry was
then left to stir in a heated stirrer block with magnetic stirring
capabilities at 50.degree. C. After 3 days, the sample was removed
from the plate, the cap taken off and the slurry left to dry under
ambient conditions before it was analysed by XRPD and DSC. This
form (Form 2) was determined to be crystalline by XRPD and seen to
be different to the previous form. This material had a melting
point of 310.9.degree. C. (onset). It had 2 theta peaks measured
using CuKa radiation at 18.0 and 17.7.degree.. When the melting
point was later measured using DSC, it was found to be
309.9.degree. C.
Example 2
4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
(Form 3)
[0267] Approximately 20 mg of
4-[4-(2-adamantylcarbamoyl)-5-tertbutyl-pyrazol-1-yl]benzoic acid
(form 1) was placed in a vial with a magnetic flea, and
approximately 2 ml of methanol added, the vial was then sealed
tightly with a cap and left to stir on a magnetic stirrer plate.
After 3 days, the sample was removed from the plate, the cap taken
off and the slurry left to dry under ambient conditions before it
was analysed by XRPD and DSC. This form (Form 3) was determined to
be crystalline by XRPD and seen to be different to previously seen
forms. This material had a melting point of 309.4.degree. C.
(onset). It had 2 theta peaks measured using CuKa radiation at 18.7
and 11.7.degree.. When the melting point was later measured using
DSC, it was found to be 309.3.degree. C.
Example 3
4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
(Form 4)
[0268] Approximately 20 mg of
4-[4-(2-adamantylcarbamoyl)-5-tertbutyl-pyrazol-1-yl]benzoic acid
as Form 1 and 20 mg of the Form 3 material was placed in a vial
with a magnetic flea, and approximately 2 ml of ethyl acetate
added, the vial was then sealed tightly with a cap and left to stir
on a magnetic stirrer plate. After 3 days, the sample was removed
from the plate, the cap taken off and the slurry left to dry under
ambient conditions before it was analysed by XRPD and DSC. This
form (Form 4) was determined to be crystalline by XRPD and seen to
be different to previously seen forms. This material (Form 4) had a
melting point of 309.1.degree. C. (onset).). It had 2 theta peaks
measured using CuKa radiation at 16.2 and 20.6.degree.. When the
melting point was later measured using DSC, it was found to be
312.0.degree. C.
[0269] Alternatively, acetonitrile may be used as the solvent at
elevated temperature: Acetonitrile (800 ml, 8.0 rel.vol) was added
to dry pure product
((4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic
acid form 1 (80.0 g) added and the slurry was heated to 75 to
78.degree. C. The reaction was maintained at 75 to 78.degree. C.
for 72.0 hr, then cooled to 20 to 25.degree. C. and stirred for 1.0
hr at 20 to 25.degree. C. The product was filtered and sucked dry.
It was then washed with acetonitrile (240.0 ml, 3.0 rel.vol) and
sucked dried for 30.0 min. The product was then dried under vacuum
(100 mbar) at 50.degree. C. for 16.0 hrs to give
4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid
Form-4 (72.0 g, 90.0%). Form-4 material (50 mg, 1% w/w, seed) was
added to a suspension of
(4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic
acid (form 1) 5.0 g in acetonitrile 50.0 ml and heated to
75-78.degree. C. for 12 to 18 hrs. The reaction was cooled to 20 to
25.degree. C. and stirred for 1.0 hr at 20 to 25.degree. C. The
product was filtered and sucked dry. It was then washed product
with acetonitrile (15 ml) and sucked dry for 5-10.0 min. The
product was then dried under vacuum (100 mbar) at 50.degree. C. for
16.0 hrs to give
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid
Form-4 (4.5 g, 89-90.0%).
4-[4-(2-Adamantylcarbamoyl)-5-tertbutyl-pyrazol-1-yl]benzoic acid
as prepared above (Form 1) was suspended in acetonitrile (7 vol),
seeded with 5 g of (form 4) and slurried at reflux for 3 days
(jacket temperature 85.degree. C.). A sample was taken and checked
by DSC (shows 2 peaks). The sample was stirred at reflux for a
further 3 days (weekend), cooled to 20.degree. C., filtered, washed
through with acetonitrile then diethyl ether, sucked dry and dried
under vacuum at 50.degree. C. for 48 hours to give a pale yellow
solid (Form 4) (90%).
[0270] Alternatively:
Tetrahydrofuran (9.0 rel. vol) and water (0.5 rel vol) were added
to 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic
acid form 1 (20.0 g, 0.047 mol) and the mixture stirred for 15
minutes and then filtered through filter paper. The residue was
washed with tetrahydrofuran (1.0 rel. vol) and the combined
filtrate transferred to a reactor and the reaction temperature
raised to 58 to 62.degree. C. Acetonitrile (20.0 rel. vol) was
added whilst maintaining the reaction at 55 to 65.degree. C. The
reaction temperature was raised to 68.+-.2.degree. C., maintained
there for 22 hours, then cooled to 20 to 25.degree. C. and stirred
for 2 hours. The product was filtered and the bed washed with
acetonitrile (5.0 rel. vol). The wet cake was dried under vacuum
(50-100 mbar) at 45 to 50.degree. C. for 4 hours to give polymorph
4 (yield 80%) as confirmed by XRPD.
[0271] Alternatively:
Tetrahydrofuran (10.0 rel. vol) was added to
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid
form 1 (5.0 g, 0.012 mol) and the temperature raised to 58 to
62.degree. C. Acetonitrile (20.0 rel. vol) was added whilst
maintaining the reaction at 55 to 65.degree. C. The temperature of
the reaction was maintained at 68.+-.2.degree. C. for 20 hours. The
contents were cooled to 20 to 25.degree. C. and stirred for 2
hours. The product was filtered and the wet cake washed with
acetonitrile (5.0 vol) and then dried in a vacuum oven (50-100
mbar) at 45 to 50.degree. C. for 4 hours to give polymorph 4 (yield
90%) as confirmed by XRPD and Solid state NMR.
[0272] Alternatively:
N,N-Dimethylformamide (5.0 rel. vol) and acetonitrile (5.0 vol)
were added to
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid
form 1 (5.0 g, 0.012 mol) and the reaction temperature raised to 60
to 65.degree. C. Acetonitrile (15.0 rel. vol) was added whilst
maintaining the temperature at 55 to 65.degree. C. The temperature
of the reaction was raised to 75 to 78.degree. C. and maintained
there for 20 hours. The contents were cooled to 20 to 25.degree. C.
and stirred for 2 hours. The product was filtered and bed washed
with acetonitrile (5.0 rel. vol) and then dried in a vacuum oven
(50-100 mbar) at 45 to 50.degree. C. for 4 hours to give polymorph
4 (yield 88%) as confirmed by XRPD.
[0273] Alternatively:
Acetic acid (10.0 rel. vol) was added to
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid
form 1 (5.0 g, 0.012 mol) and the temperature raised to 75 to
78.degree. C. Acetonitrile (20.0 rel. vol) was added whilst
maintaining the temperature at 70 to 78.degree. C. The mixture was
stirred at 75 to 78.degree. C. and maintained there for 22 hours.
The contents were cooled to 20 to 25.degree. C. and stirred for 2
hours. The product was filtered and the bed washed with
acetonitrile (5.0 rel. vol) and then dried in a vacuum oven (50-100
mbar) at 45 to 50.degree. C. for 4 hours to polymorph 4 (yield 66%)
as confirmed by XRPD.
[0274] Alternatively:
2-Methyl-THF (10.0 rel. vol) was added to
4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid
form 1 (5.0 g, 0.012 mol) and the temperature raised to 70 to
75.degree. C. Acetonitrile (20.0 rel. vol) was added whilst
maintaining the temperature at 70 to 75.degree. C. and then allowed
to stir at 75 to 78.degree. C. for 23 hours. The contents were
cooled to 20 to 25.degree. C. and stirred for 2 hours. The product
was filtered and the bed washed with acetonitrile (5.0 rel. vol)
and then dried in a vacuum oven (50-100 mbar) at 45 to 50.degree.
C. for 4 hours to give polymorph 4 (yield 93%) as confirmed by
XRPD.
[0275] Alternatively:
4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid
(form 1--prepared as in reference example 2) (20.0 g, 0.047 mol)
followed by tetrahydrofuran (9.0 rel. vol) and water (0.5 rel vol)
were added to a suitable jacketed reactor. The contents were
stirred for 15 minutes, filtered through filter paper and washed
with tetrahydrofuran (1.0 rel. vol). The combined filtrate was
transferred to reactor and temperature of mass increased to 58 to
62.degree. C. Acetonitrile (20.0 rel. vol) was added whilst
maintaining the temperature at 55 to 65.degree. C. The temperature
of reaction mass was increased to 68.+-.2.degree. C. and maintained
there for 22 hours. The contents were cooled to 20 to 25.degree. C.
and stirred for 2 hours. The product was filtered and the bed
washed with acetonitrile (5.0 rel. vol). The wet cake was dried
under vacuum (50-100 mbar) at 45 to 50.degree. C. for 4 hours to
yield polymorph form 4 (80%).
* * * * *